HOME >> BIOLOGY >> NEWS
Targeted therapy for lung cancer patients shows promise in extending lives

ng molecular profiling on each patient's tumor will enable us to identify patients who are more likely to respond and to have a favorable response. We are looking to achieve tumor shrinkage with minimal side effects. We are hopeful that this type of research will provide a kinder, gentler, more effective therapy for lung cancer patients.

"This is the most exciting thing going on in lung cancer today. For the next two decades, this will be the wave of the future in treatment."

Patients with stage IV lung cancer who receive one course of chemotherapy have side effects of nausea, vomiting and can feel worn down. This two-pill combination is not chemotherapy, and it's less toxic to the body; patients do not experience nausea and vomiting. The targeted therapy can help some patients feel better and live longer. The side effects of these pills, which are less bothersome than that of traditional chemotherapy, include an acne-like rash and diarrhea.

Bonomi says that such seriously ill lung cancer patients might be expected to live four to six months without treatment. Tarceva, one of the combination drugs, has recently been reported to increase survival. In general, survival improvement for patients with advanced stage lung cancer have been modest- adding several months to longevity. "And while that doesn't seem like a lot of time, that may mean a lot to cancer patients planning to attend a graduation, anniversary or upcoming birthday in the next few months."

Over 170,000 new incidences of lung cancer are reported every year.

The other sites in the study are Rush North Shore, Skokie, Ill.; Northwestern Memorial Hospital, Chicago, and Vanderbilt University Medical Center, Nashville.

To enroll in the study, please call 312-942-5687.


'"/>

Contact: Mary Ann Schultz
mary_ann_schultz@rush.edu
312-942-7816
Rush University Medical Center
22-Jun-2004


Page: 1 2

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. Targeted immunotherapy eradicates cancer in mice
3. Targeted radiation to liver tumors spares tissue, improves quality of life
4. Targeted Genetics presents data on arthritis gene therapy
5. Targeted genetics presents promising data from cystic fibrosis clinical trial
6. Targeted Genetics presents clinical data on E1A cancer gene therapy
7. Targeted Genetics presents advances in systemic gene delivery technology
8. Targeted Genetics presents advances in synthetic gene delivery technologies
9. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
10. Fred Hutchinson Cancer Research Center And Targeted Genetics Announces Issuance Of Braod Patent Covering Antigen-Specific T Cell Expansion
11. Marine Snail Toxin Targeted At African Toad Eggs Reveals Novel Impact On The Regulation Of Serotonin

Post Your Comments:
(Date:8/5/2015)... York , August 5, 2015 ... report titled "Facial Recognition Market - Global Industry Analysis, ... the global market for facial recognition is forecast to ... driven by increased demand for surveillance systems by civil ... rising number of crimes and terrorist activities across the ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, ... second US laboratory is to open in Manhattan, Kansas in early October, 2015. ... long-term growth of research and development through collaboration with researchers from Kansas State ...
(Date:8/26/2015)... (PRWEB) , ... August 26, 2015 , ... ... is increasing its investment in the development and manufacture of highly valued cardiac ... The company’s scientific team's extensive expertise with protein chemistry has led to the ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation ... announced today the closing of its previously announced public ... by the underwriters of their option to purchase an ... offering price of $41.00 per share.  The exercise of ... of common stock sold by Intrexon to 5,609,756 shares ...
(Date:8/26/2015)... 2015 After litigating and negotiating patent ... to P2i United States patent RE43,651 ... the United States without any admission ... either party. As a result of the parties, settlement, the ... California dismissed the case without prejudice. ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2
Cached News: